

# Thymoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/T9C154A00933EN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T9C154A00933EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Thymoma – Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Thymoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Thymoma Understanding

#### Thymoma: Overview

Thymomas are rare indolent tumours of the anterior superior mediastinum. Despite a benign histologic appearance, some thymomas invade nearby structures or metastasize. The exact cause of thymomas is unknown. Thymomas are equally common in men and in women and are most frequently seen in the fourth and fifth decades of life. There are no known risk factors that predispose a person to developing thymoma. Patients are commonly asymptomatic, but some may present with unusual paraneoplastic syndromes such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia. Since tumour biopsy may potentially disrupt the thymic capsule, it is often not performed. Patients are therefore diagnosed and staged at the time of definitive surgery. Thymomas can generally be categorized into two stages: non-invasive and invasive. Prognosis closely parallels the disease stage. Surgery is the

principal treatment and is curative in early stage disease. Radiation therapy, either alone or in combination with chemotherapy, is an option for both incompletely or completely resected disease. Chemotherapy is offered to patients with locally advanced, recurrent, or metastatic thymoma, with excellent responses and prolonged survival.

'Thymoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thymoma pipeline landscape is provided which includes the disease overview and Thymoma treatment guidelines. The assessment part of the report embraces, in depth Thymoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thymoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Thymoma R&D. The therapies under development are focused on novel approaches to treat/improve Thymoma.

## Thymoma Emerging Drugs Chapters

This segment of the Thymoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Thymoma Emerging Drugs

Milciclib: Tiziana Life sciences

Tiziana's Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomyosin receptor kinases and Src family kinases controlling cell growth and malignant progression of cancer was exclusively licenced in January 2015

from Nerviano Medical Sciences. Milciclib has demonstrated safety in 316 patients with advanced solid cancers in Phase 1 and 2 studies and shown indications of efficacy. In two, completed, Phase 2 thymic cancer trials, Milciclib successfully increased overall survival and met both primary and secondary endpoints. Milciclib was granted orphan designation by the European Commission and by the U.S. Food and Drug Administration ('FDA') for the treatment of Thymoma and an aggressive form of thymic carcinoma in patients previously treated with chemotherapy.

#### Pembrolizumab: Merck Sharp & Dohme Corp

Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated in Phase II clinical trials for the treatment of patients with Thymoma.

Further product details are provided in the report..

#### Thymoma: Therapeutic Assessment

This segment of the report provides insights about the different Thymoma drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Thymoma

There are approx. 8+ key companies which are developing the therapies for Thymoma. The companies which have their Thymoma drug candidates in the most advanced stage, i.e. Phase II include, Tiziana Life sciences.

#### Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Thymoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Thymoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thymoma therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thymoma drugs.

### Thymoma Report Insights

Thymoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Thymoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Thymoma drugs?

How many Thymoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thymoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thymoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Thymoma and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

Introduction

Executive Summary

Thymoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Thymoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Thymoma companies' collaborations, Licensing, Acquisition -Deal Value Trends

Thymoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Milciclib: Tiziana Life sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early stage products (Phase I)

Comparative Analysis

VMD-928: VM Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Thymoma Key Companies

Thymoma Key Products

Thymoma- Unmet Needs

Thymoma- Market Drivers and Barriers

Thymoma- Future Perspectives and Conclusion

Thymoma Analyst Views

Thymoma Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Thymoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Thymoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Thymoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T9C154A00933EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9C154A00933EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970